DS
HRTX icon

David Shaw’s Heron Therapeutics HRTX Stock Holding History

David Shaw’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.4K Sell
120,435
-2,480,555
-95% -$1.99M ﹤0.01% 4699
2026
Q1 		$2.08M Sell
2,600,990
-403,650
-13% -$468K ﹤0.01% 2883
2025
Q4 		$3.91M Sell
3,004,640
-83,852
-3% -$104K ﹤0.01% 2511
2025
Q3 		$3.89M Sell
3,088,492
-111,807
-3% -$177K ﹤0.01% 2439
2025
Q2 		$6.62M Buy
3,200,299
+214,102
+7% +$437K ﹤0.01% 1808
2025
Q1 		$6.57M Sell
2,986,197
-737,509
-20% -$1.43M 0.01% 1699
2024
Q4 		$5.7M Sell
3,723,706
-660,971
-15% -$1.07M ﹤0.01% 1865
2024
Q3 		$8.73M Buy
4,384,677
+521,302
+13% +$1.24M 0.01% 1512
2024
Q2 		$13.5M Buy
3,863,375
+1,168,329
+43% +$3.59M 0.01% 1143
2024
Q1 		$7.47M Buy
2,695,046
+1,404,049
+109% +$3.53M 0.01% 1587
2023
Q4 		$2.19M Buy
1,290,997
+1,045,724
+426% +$1.15M ﹤0.01% 2596
2023
Q3 		$253K Sell
245,273
-103,687
-30% -$148K ﹤0.01% 3691
2023
Q2 		$405K Sell
348,960
-372,122
-52% -$664K ﹤0.01% 3502
2023
Q1 		$1.09M Sell
721,082
-65,998
-8% -$165K ﹤0.01% 3098
2022
Q4 		$1.97M Sell
787,080
-112,491
-13% -$362K ﹤0.01% 2953
2022
Q3 		$3.8M Sell
899,571
-715,411
-44% -$2.8M ﹤0.01% 2387
2022
Q2 		$4.51M Sell
1,614,982
-419,247
-21% -$1.68M 0.01% 2248
2022
Q1 		$11.6M Buy
2,034,229
+683,738
+51% +$5M 0.01% 1468
2021
Q4 		$12.3M Sell
1,350,491
-81,438
-6% -$831K 0.01% 1473
2021
Q3 		$15.3M Sell
1,431,929
-532,221
-27% -$6.48M 0.01% 1196
2021
Q2 		$30.5M Sell
1,964,150
-243,240
-11% -$3.87M 0.03% 791
2021
Q1 		$35.8M Sell
2,207,390
-53,888
-2% -$961K 0.03% 639
2020
Q4 		$47.9M Buy
2,261,278
+168,612
+8% +$2.93M 0.04% 511
2020
Q3 		$31M Sell
2,092,666
-25,776
-1% -$402K 0.03% 608
2020
Q2 		$31.2M Sell
2,118,442
-206,661
-9% -$3.4M 0.04% 555
2020
Q1 		$27.3M Sell
2,325,103
-519,946
-18% -$9.77M 0.04% 480
2019
Q4 		$66.9M Buy
2,845,049
+1,207,750
+74% +$26.7M 0.08% 307
2019
Q3 		$30.3M Buy
1,637,299
+265,008
+19% +$4.88M 0.04% 590
2019
Q2 		$25.5M Sell
1,372,291
-99,305
-7% -$1.98M 0.03% 635
2019
Q1 		$36M Buy
1,471,596
+417,588
+40% +$10.9M 0.05% 478
2018
Q4 		$27.3M Buy
1,054,008
+473,127
+81% +$13M 0.04% 570
2018
Q3 		$18.4M Buy
580,881
+142,648
+33% +$5.31M 0.02% 815
2018
Q2 		$17M Sell
438,233
-537,780
-55% -$17.1M 0.02% 806
2018
Q1 		$26.9M Buy
976,013
+480,381
+97% +$10.9M 0.04% 541
2017
Q4 		$8.97M Buy
495,632
+255,457
+106% +$4.17M 0.01% 1098
2017
Q3 		$3.88M Buy
240,175
+182,875
+319% +$2.87M 0.01% 1565
2017
Q2 		$794K Buy
57,300
+28,048
+96% +$406K ﹤0.01% 2552
2017
Q1 		$439K Buy
29,252
+15,132
+107% +$209K ﹤0.01% 2788
2016
Q4 		$185K Buy
+14,120
New +$222K ﹤0.01% 3279
2016
Q3 		– Sell
-57,850
Closed -$1.04M – 3434
2016
Q2 		$1.04M Buy
57,850
+8,180
+16% +$160K ﹤0.01% 2386
2016
Q1 		$943K Buy
+49,670
New +$980K ﹤0.01% 2395
2015
Q4 		– Sell
-60,281
Closed -$1.47M – 3881
2015
Q3 		$1.47M Sell
60,281
-168,657
-74% -$5.62M ﹤0.01% 2319
2015
Q2 		$7.13M Buy
228,938
+216,205
+1,698% +$4.07M 0.01% 1226
2015
Q1 		$185K Sell
12,733
-6,877
-35% -$77.5K ﹤0.01% 3462
2014
Q4 		$197K Buy
+19,610
New +$160K ﹤0.01% 3810

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

David Shaw's HRTX Position: Q2 2026 in Review

David Shaw reduced its Heron Therapeutics (HRTX) stake by 95% in Q2 2026, selling an estimated $1.99M and leaving 120,435 shares worth $51.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4699.

David Shaw first reported a position in HRTX in Q4 2014 and has held it in 45 quarters since. The position peaked at $66.9M in Q4 2019. 161 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • David Shaw held 120,435 shares of Heron Therapeutics worth $51.4K as of Q2 2026.
  • David Shaw sold 2,480,555 Heron Therapeutics shares in Q2 2026, an estimated $1.99M.
  • Heron Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4699 holding.
  • David Shaw first reported a position in Heron Therapeutics in Q4 2014 and has held it in 45 quarters since.
  • David Shaw's Heron Therapeutics position peaked at $66.9M in Q4 2019.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.